The burgeoning landscape of emerging treatments for body management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a comparable https://brendaewta107117.wikimidpoint.com/6386443/retatrutide_vs_tirzepatide_a_comparative_analysis